Hemlibra (emicizumab-kxwh) Letter of Medical Necessity
Hemlibra (emicizumab-kxwh) is an extremely high-cost specialty therapy ($400K+ annually) with stringent prior authorization requirements. A complete Letter of Medical Necessity documenting diagnosis, inhibitor status, and bleeding history is essential.
FDA-Approved Indications
- ● hemophilia A (with or without factor VIII inhibitors) — routine prophylaxis to prevent or reduce bleeding episodes
Why Hemlibra Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Hemophilia A diagnosis not confirmed by factor VIII activity assay
- 2. Inhibitor titer (Bethesda units) not documented when applicable
- 3. Bleeding episode history not specified
- 4. Specialty pharmacy enrollment incomplete
- 5. Concurrent activated prothrombin complex concentrate not addressed (TMA risk)
What to Include in a Hemlibra Letter of Medical Necessity
Document confirmed hemophilia A by factor VIII activity (<1% severe, 1-5% moderate), genetic testing when available, inhibitor status with current Bethesda titer, annualized bleeding rate on prior therapy, target joints and prior arthropathy, and a plan addressing concurrent bypassing agent restrictions to mitigate thrombotic microangiopathy risk.
Key clinical evidence to cite:
- ✓ HAVEN 1, 2, 3, 4 trials — significant reduction in annualized bleeding rate
- ✓ Real-world registry data confirming efficacy in non-inhibitor patients
- ✓ Long-term safety data >5 years
Relevant guidelines:
- 📖 MASAC Hemophilia Treatment Guidelines
- 📖 WFH 2020 Hemophilia Management Guidelines
Hemlibra Prior Authorization Criteria
Standard criteria across major US payers for Hemlibra. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Hemlibra
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Hemlibra Prior Authorization FAQ
Why was my Hemlibra prior authorization denied?
The most common denial reasons for Hemlibra are: Hemophilia A diagnosis not confirmed by factor VIII activity assay; Inhibitor titer (Bethesda units) not documented when applicable; Bleeding episode history not specified; Specialty pharmacy enrollment incomplete; Concurrent activated prothrombin complex concentrate not addressed (TMA risk).
What should a Hemlibra Letter of Medical Necessity include?
Document confirmed hemophilia A by factor VIII activity (<1% severe, 1-5% moderate), genetic testing when available, inhibitor status with current Bethesda titer, annualized bleeding rate on prior therapy, target joints and prior arthropathy, and a plan addressing concurrent bypassing agent restrictions to mitigate thrombotic microangiopathy risk.
Which payers cover Hemlibra?
Hemlibra is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.